JNNP:GFAP作为额颞叶痴呆和原发性精神疾病的生物标志物:诊断和预后表现

2021-07-10 MedSci原创 MedSci原创

额颞叶退行性变(FTLD)的异质性临床病理包括一大组进行性神经退行性疾病,其中行为变异性额颞叶痴呆(bvFTD)和原发性进行性失语(PPA)是主要的临床亚型。导致FTLD最常见的遗传原因是C9orf7

额颞叶退行性变(FTLD)的异质性临床病理包括一大组进行性神经退行性疾病,其中行为变异性额颞叶痴呆(bvFTD)和原发性进行性失语(PPA)是主要的临床亚型。导致FTLD最常见的遗传原因是C9orf72的六核苷酸重复序列扩增和GRN、MAPT基因突变。 FTLD病例中有相当一部分(12%–51%,取决于表型)首先被误分类为原发性精神障碍(PPD例如,双相情感障碍、重度抑郁障碍或精神分裂症),导致诊断延迟、用药不当、医疗费用增加以及患者及其护理人员的负担增加。 最近的研究表明,反映中枢神经系统(CNS)损伤和病理生理过程的神经丝蛋白和其他基于血液的生物标记物,对于区分精神病和神经退行性疾病患者具有潜在的有用生物标记物。 

胶质原纤维酸性蛋白(GFAP)是一种在中枢神经系统星形胶质细胞中表达的丝状蛋白。脑脊液(CSF)或血液中高水平的GFAP与星形胶质细胞的过度活化和变性有关,并被认为是星形胶质细胞死亡、星形胶质细胞增生、脑胶质细胞变性的标志物。目前的超灵敏免疫分析平台能够可靠地测量脑脊液和血液中的GFAP水平。在这项研究中,目的是比较血清中GFAP(sGFAP)和全血中GFAP(bGFAP)的水平,在一组由FTLD或PPD引起的异质性神经精神和认知障碍患者和健康对照组中。评估了sGFAP水平与C9orf72重复序列扩增(由于其与星形胶质细胞增生有关)、FTLD患者的生存时间以及FTLD和PPD患者的横断面和纵向脑萎缩之间的关系。

151例患者,其中107例最终诊断为FTLD,44例为PPD。这些患者是在1998-2019年间招募的。在FTLD队列中,75名患者患有bvFTD,23名患者患有PPA(20名非流出物变体(nfvPPA)和3名语义变体(svPPA)),9名患者患有运动神经元疾病(FTLD-MND)。全血和血清样本是在门诊首次诊断就诊时采集的,可以检测这些患者的早期生物标志物改变。所有FTLD患者至少符合bvFTD、PPA或FTLD-MND的可能标准(26例因C9orf72重复扩张或神经病理学确认而确诊)。PPD队列包括具有严重迟发性精神病表型的患者,这些患者在随访中最终没有显示任何进行性神经退行性疾病。十八名超过60岁的非痴呆对照者被招募到芬兰东部大学脑研究单位进行研究。所有研究参与者都接受了人口统计学访谈、神经状态检查和认知评估。仅提供全血样本。

Figure 3

FTLD患者sGFAP水平与萎缩率的相关性

与PPD组或对照组相比,FTLD组sGFAP和bGFAP水平升高。工作特性分析表明FTLD和PPD之间具有良好的诊断性能(曲线下面积(AUC)=0.820,95% 置信区间0.745至0.896)。sGFAP和bGFAP水平显示出很强的相关性,sGFAP水平升高与颞叶皮质萎缩率显著相关,并预测FTLD患者的生存时间缩短。未检测到与C9orf72重复扩增相关。FTLD患者的sGFAP水平明显高于PPD患者,这使得FTLD患者与PPD患者的鉴别成为可能。sGFAP和sNfL联合检测的敏感性和特异性均高于单独检测。此外,在随访中,sGFAP水平与FTLD患者的生存时间显著缩短和更严重的年化脑萎缩率相关,这意味着sGFAP水平也可能具有预后价值,尤其是与sNfL水平相结合。对一组患者的比较显示,与PPD患者相比,FTLD患者的bGFAP水平也升高。此外,FTLD患者bGFAP水平显著高于健康对照组,而PPD患者bGFAP水平与健康对照组无显著差异。

Figure 5

采集血样后的存活率

sGFAP能区分FTLD和PPD患者,并与FTLD患者生存期缩短和严重脑萎缩率增高有关些。结果表明,基于血液的GFAP在FTLD和PPD患者的鉴别诊断以及FTLD的疾病进展和星形胶质细胞增生的评估中是一种微创和有意义的生物标志物。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-11-22 mnda
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2022-01-18 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1846983, encodeId=517a184698355, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Apr 07 21:05:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970979, encodeId=9b5b19e09798d, content=<a href='/topic/show?id=4e1ee98203' target=_blank style='color:#2F92EE;'>#GFAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7982, encryptionId=4e1ee98203, topicName=GFAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Mon Nov 22 14:05:02 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968675, encodeId=6cf019686e53c, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 18 04:05:02 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841703, encodeId=8fd51841e03fc, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 13 05:05:02 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561049, encodeId=437315610492c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567058, encodeId=54a9156e058b6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Jul 12 02:05:02 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048831, encodeId=c760104883108, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Jul 10 14:05:02 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-07-10 junJUN

    老年人痴呆何药可用??

    0

相关资讯

Br J Cancer:治疗后炎症相关生物标志物与结直肠癌患者生存之间的关联性研究

炎症反应在结直肠癌(CRC)的发生发展中起着至关重要的作用。

ATVB:咀嚼能力与心血管疾病风险生物标志物的关系

与咀嚼能力较差相关的饮食改变以及由此导致的腹部肥胖可能导致IL-6水平升高和NTproBNP水平降低。

ASCO 2021:摘要概览与展望21:zenocutuzumab治疗晚期胰腺癌、NRG1融合实体肿瘤的有效性和安全性

NRG1基因融合是一种罕见但是强有力的癌症驱动因素,常常出现在胰腺癌、肺癌和其他实体瘤中。

Angiogenesis:可预测贝伐单抗诱发高血压风险的血浆生物标志物

血管生成素-2、VEGF-A和VCAM-1水平降低与贝伐单抗诱导性高血压风险升高相关

npj Precision Oncology :研究员发现了一种胰腺癌的生物标志物!

研究人员发现了一种可用于帮助诊断胰腺癌的蛋白质, (PTX3) 可能是一种敏感且特异的生物标志物,能够区分胰腺癌和其他癌症。

Cancers:晚期胃食管癌免疫疗法的生物标志物

当前晚期胃食管癌(GEC)的预后很差,可选择的治疗方案有限。包括抗程序化死亡-1(PD-1)抗体pembrolizumab和nivolumab在内的免疫疗法已经被批准用于GEC的治疗。此外,近期的大型